Browsing Tag
healthcare stocks
5 posts
Is Fulgent Genetics rebuilding itself as a pathology-first diagnostics platform after losing a major customer?
Fulgent Genetics targets $350M 2026 revenue as pathology expansion reshapes its customer mix. Read how the strategy could stabilise growth.
FDA clears Bysanti and suddenly Vanda Pharmaceuticals Inc has no margin for execution failure
FDA approval of Bysanti sends Vanda Pharmaceuticals Inc stock higher. Read why execution now matters more than hype in schizophrenia and bipolar markets.
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!
Why 4DMedical (ASX: 4DX) stock is gaining momentum after A$22.6m option exercise and cash runway boost
4DMedical (ASX: 4DX) raises A$22.6m via option exercise, boosting its cash balance to A$45.5m. Investors eye CT:VQ rollout and RSNA 2025 milestones.
Regenerative medicine firm Organogenesis stock skyrockets 73% after surprise Q4 profit
Organogenesis Holdings Inc., a leading player in regenerative medicine, has reported a fourth-quarter profit that significantly exceeded market…